SCOTUS rejects BMS vs Gilead patent clash

10-11-2022

Staff Writer

SCOTUS rejects BMS vs Gilead patent clash

Shutterstock / Corona Borealis Studio

Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.


Gilead, Kite Pharma, Juno Pharmaceuticals, Sloan Kettering, Yescarta, CAR-T, patent infringement, SCOTUS, Supreme Court, US, big pharma, generics

LSIPR